ArticleLiver cancer2024

Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".

Masatoshi Kudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.